Internship

UX Research Intern

Posted on 2/4/2025

Click Therapeutics

Click Therapeutics

51-200 employees

Develops software as prescription medical treatments

Compensation Overview

$22/hr

New York, NY, USA

This is a hybrid internship requiring in-office presence on Wednesdays and Fridays.

Category
Product & UX/UI Design
UI/UX & Design
Required Skills
UI/UX Design
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Click Therapeutics referral from your network.

đź’ˇ

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Rising Sophomore or Junior currently pursuing an undergraduate degree.
  • A portfolio showing an established basic foundation of user research practices.
  • Familiarity with design-thinking methodology.
  • Attention to detail, analytical, data-driven, and focused on end-user needs.
  • Passionate about design, user experience, and UX best practices.
  • Excellent written and oral communication skills.
Responsibilities
  • Collaborate with research, design, product, and science and serve as the patient advocate.
  • Help conduct generative and evaluative research.
  • Write research screeners, interview guides and/or unmoderated study questions.
  • Conduct user interviews and/or facilitate unmoderated UX studies.
  • Synthesize research and build reports that communicate insights, helping others understand the needs of our patients.
  • Support other projects but also work on your own summer project doing research with patients.
Desired Qualifications
  • Interest or experience in healthcare.

Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they can be used independently or alongside traditional treatments. The applications undergo rigorous testing through randomized controlled trials to ensure they are safe and effective before seeking FDA clearance to be marketed as class II medical devices. Revenue is generated from physicians who prescribe these apps and from payers who reimburse for them. Click Therapeutics also collaborates with other healthcare companies, such as Boehringer Ingelheim, to enhance their offerings, exemplified by a significant partnership aimed at treating schizophrenia. The company's goal is to provide effective digital solutions for unmet medical needs, continuously improving their applications using real-world evidence.

Company Size

51-200

Company Stage

Debt Financing

Total Funding

$161.6M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA authorization for CT-132 boosts their credibility in digital therapeutics.
  • Acquisition of Better Therapeutics expands their portfolio into obesity and cardiometabolic diseases.
  • Collaborations with Otsuka and Boehringer Ingelheim strengthen their market position.

What critics are saying

  • Integration challenges with Better Therapeutics' assets may delay product development.
  • Regulatory hurdles could impact approval timelines for new digital therapeutics.
  • Dependence on partnerships could affect market reach if collaborations change.

What makes Click Therapeutics unique

  • Click Therapeutics specializes in software as medical treatments for unmet medical needs.
  • Their Clickometrics® platform personalizes user experience to optimize engagement and outcomes.
  • Partnerships with pharma giants like Boehringer Ingelheim enhance their market credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Company Match

Unlimited Paid Time Off

Flexible Work Arrangement

Stock Options

Performance Bonus

Fertility Treatment Support

Professional Development Budget

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

↑ 1%

1 year growth

↑ 6%

2 year growth

↑ 7%
Hit Consultant
Apr 15th, 2025
Click Therapeutics Obtains Fda Authorization For First Prescription Digital Therapeutic For Migraine Prevention

What You Should Know: â€“ Click Therapeutics, Inc. (“Click”), a leader in the rapidly evolving field of prescription medical treatments, encompassing both prescription digital therapeutics (PDTs) and software-enhanced drug™ therapies has received FDA marketing authorization for CT-132, the first prescription digital therapeutic specifically indicated for the preventive treatment of episodic migraine in adults aged 18 and older.– The FDA granted a De Novo Classification Request for CT-132, signifying the novel nature of this digital intervention. This PDT is intended for adjunctive use alongside existing acute and/or other preventive migraine treatments, offering patients an additional tool in their management strategy.CT-132 Prescription Digital TherapeuticThe CT-132 prescription digital therapeutic is indicated for the preventive treatment of episodic migraine in patients 18 years of age and older. It is intended for adjunctive use alongside acute and / or other preventive treatments for migraine. The FDA’s decision was primarily based on compelling data from the pivotal ReMMi-D (Reduction in Monthly Migraine Days, NCT05853900) study. This study evaluated CT-132 in patients already taking standard-of-care prescription migraine medications (including acute, first-line preventive, and second-line preventive treatments) and successfully met its primary endpoint of significantly reducing monthly migraine days.ReMMi-D and ReMMiD-C StudiesFurther supporting the authorization were results from the ReMMiD-C bridging study (NCT06004388)

Business Wire
Mar 20th, 2025
Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience With Investment in Click Therapeutics for Digital Therapeutics Beyond Clinical Trials

Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced its investment in Click Therapeutics, a leader in prescription digital therapeutics ...

The Healthcare Technology Report
Nov 28th, 2024
Click Therapeutics Launches Software-Enhanced Drug Therapies

Click Therapeutics launches Software-Enhanced Drug therapies.

Business Wire
Oct 8th, 2024
Click Therapeutics Founder and CEO David Benshoof Klein Named to 2024 PharmaVoice 100 List

NEW YORK-(BUSINESS WIRE)-David Benshoof Klein, founder and chief executive officer of Click Therapeutics, has been honored as a PharmaVoice 100 winner.

Business Wire
Aug 13th, 2024
Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn(TM), the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

PRINCETON, N.J. & NEW YORK-(BUSINESS WIRE)-Otsuka Precision Health, Inc. (OPH) and Click Therapeutics, Inc., (Click) announce today the commercial launch of Rejoyn(TM).

INACTIVE